Cardiorenal disease is a common, serious and costly condition. It is characterised by simultaneous kidney and heart failure while the primarily failing organ may be either the heart or the kidney. Managing or even preventing this complex but common situation can be challenging as comorbidities require care provision by different medical specialties administering often contradicting and interacting treatment regiments.
CARRE offers an integrated approach to self-monitoring and planning for cardiorenal disease prevention and management. The patient can use CARRE to aggregate personal medical data from personal health record systems and to enrich this with measurements on physical activity, body weight, blood pressure and blood glucose as acquired by a variety of commercially available personal sensors. Measurement and other medical data are used to provide personalized risk assessment.
Check out the CARRE service:
Explore current developments on our working test deployment (which can occasionally prove unstable).
Preliminary results of a randomized control trial in the two pilot sites, (55 patients using CARRE and 43 controls), show an increase in health literacy by 9.8% and an increase in empowerment by 8.0% in patients who used CARRE service for 2 months. In particular, empowerment was 12.4% in patients with metabolic syndrome, while health literacy was increased by 21.3% in patients with heart failure of chronic kidney disease. In terms of system usability, participants reported an above average assessment, corresponding to an acceptable system. For details on evaluation, check D.7.4.